Cells were maintained in DMEM (HCT116, SW480, U2OS), MEM- with 1 ng ml 1 fibroblast growth factor 2 (Peprotech, hMSC) or DMEM with 1% non-essential amino acid (Gibco) and 50 g ml 1 uridine (Sigma-Aldrich) supplementation (143B), with 10% dialysed foetal bovine serum (dFBS), 50 U ml 1 penicillin and streptomycin (ThermoFisher, 15070063) and 1 mM sodium pyruvate (ThermoFisher, 11360070)
No regulatory body Health Canada, the FDA, the EMA, the TGA, or any equivalent has approved 5-Amino-1MQ as a drug for human or veterinary use
Most published information currently comes from: While many findings appear promising, additional research is needed to better understand long-term safety, effectiveness, dosing protocols, and potential risks in diverse patient populations
Mechanism of Action In research applications CJC-1295 (No DAC) acts as a GH releasing factor analog that will increase the secretion of GH by mimicking the function of endogenous GHRH, and Ipamorelin acts to selectively bind the ghrelin receptor to initiate another pathway of increased growth hormone production